1. All Products
  2. DINJ - Injectable drugs
  3. CABOTEGRAVIR, 200mg/ml, prolonged-release, 3ml, vial
Public Pricelist

CABOTEGRAVIR, 200mg/ml, prolonged-release, 3ml, vial

https://unicat.msf.org/cat/product/89290
NST DINJCABO6VP

Valid Article

The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
6.4.2.4 - Integrase inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AJ04
Anatomical Therapeutic Chemical Classification according to WHOCC
P
The order of this product needs to be justified and is only acceptable under certain conditions.
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

CABOTEGRAVIR prolonged-released

Non-standard article due to supply issue. Please, contact your HIV advisor for more information when ordering.

Therapeutic Action

Antiretroviral, integrase inhibitor (INI)

Prolonged-release suspension for injection

Indications

Pre-exposure prophylaxis (PrEP) of HIV infection in at-risk adults and adolescents (> 35 kg).

Some restricted information has been hidden. Sign in to see this information

Instructions for use

Each single-dose vial contains 600 mg cabotegravir in 3 ml.

Hold the vial firmly and vigorously shake for a full 10 seconds. Invert the vial and check the resuspension. It should look uniform. If the suspension is not uniform, shake the vial again. It is normal to see small air bubbles.

Must be given as slow IM injection to the ventrogluteal (recommended) or the dorsogluteal sites, every 2 months.

Precautions for Use

Contraindications: concomitant use with rifampicin, rifapentine, carbamazepine, oxcarbazepine, phenytoin or phenobarbital.

Pregnancy and breastfeeding: existing regulatory approvals do not contraindicate the use of cabotegravir in pregnant women, and indicate it could be used where the expected benefit justifies the potential risk to the foetus.

Storage

  • Below 25ºC
  • Do not freeze.
  • Once the suspension is drawn into the syringe, use the product immediately.